Nav: Home

Trial from Niger finds village-wide prophylactic antibiotics contained spread of meningitis

June 26, 2018

Distribution of single doses of the oral antibiotic ciprofloxacin to residents of rural villages in the African meningitis belt reduced the number of meningitis cases during a 2017 meningitis epidemic, according to a new study in PLOS Medicine by Matthew Coldiron and colleagues from Epicentre and Médecins Sans Frontières in France, Switzerland and Niger.

Antibiotic prophylaxis has been used to limit the spread of meningococcal meningitis, mainly in high income countries. This strategy is especially useful for scenarios where vaccines (e.g. Neisseria meningitidis serogroup C) or other prophylactic measures are not yet widely available.

In the current cluster-randomized trial, conducted during a meningococcal meningitis outbreak in the Madarounfa District, Niger, villages with detected cases of meningitis were randomly assigned to one of three intervention arms: standard care (control, without prophylactic medication), a single dose of oral ciprofloxacin for household contacts, or village-wide distribution of ciprofloxacin. The investigators compared the number of new cases in each village and household in each of the antibiotic arms to those in the village populations without antibiotic prophylaxis.

Between April and May 2017, 49 villages were included in the trial. A total of 248 meningitis cases were reported in the study. The rate of new meningitis cases was 451 per 100,000 persons in the control arm; 386 per 100,000 persons in the household prophylaxis arm (t-test versus control p=0.68); and 190 per 100,000 persons in the village-wide prophylaxis arm (t-test versus control p=0.032). The ratio of new meningitis cases between the village-wide prophylaxis arm and the control arm was 0.40 (CI [0.19?0.87], p=0.022), and the ratio between the household prophylaxis arm and the control arm was 0.94 (CI [0.52-1.73], p=0.85). One limitation of the study was the small number of cerebrospinal fluid samples sent for confirmatory testing.

The study results showed that at the end of the epidemic, the number of new meningitis cases was 60% lower in villages receiving village-wide prophylaxis whereas household prophylaxis reduced the rate of subsequent meningitis cases by only a non-significant 6%.

The authors conclude that "the persistence of seasonal meningococcal meningitis epidemics in the African meningitis belt can ultimately be broken only with an effective and affordable conjugate vaccine. In the interim, mass prophylaxis with ciprofloxacin as an epidemic response could be a valuable tool, and should continue to be evaluated."

In a linked Perspective, Keith Klugman and Rasa Izadnegahdar from the Bill and Melinda Gates Foundation in Seattle discuss results of the current trial and consider potential benefits and risks associated with antibiotic chemoprophylaxis on a broader scale in settings where vaccines are not yet available.
Research Article


Médecins Sans Frontières (MSF) provided funding for the trial. The funder helped to design and plan the study, and participated in the writing of this report, but had no role in data collection and analysis

Competing Interests:

I have read the journal's policy and the authors of this manuscript have the following competing interests: RFG is a member of the Editorial Board of PLOS Medicine.


Coldiron ME, Assao B, Page A-L, Hitchings MDT, Alcoba G, Ciglenecki I, et al. (2018) Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial. PLoS Med 15(6): e1002593.

Image Credit: numbercfoto, Pixabay

Author Affiliations:

Epicentre, Paris, France
Epicentre, Maradi, Niger
Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America
Médecins Sans Frontières, Geneva, Switzerland
Médecins Sans Frontières, Paris, France
Niamey National Hospital, Niamey, Niger vCentre de Recherche Médicale et Sanitaire, Niamey, Niger
Ministry of Public Health, Madarounfa, Niger
Department of Internal Medicine, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Paris, France
IAME Research Group UMC1137, Université Paris Diderot, Paris, France

In your coverage please use this URL to provide access to the freely available paper:



The authors received no specific funding for this work, but wish to disclose that the MORDOR study was funded by the Bill and Melinda Gates Foundation.

Competing Interests:

The authors have declared that no competing interests exist.


Klugman KP, Izadnegahdar R (2018) Antibiotic prophylaxis--Preventing severe infections and saving lives in developing countries with very high mortality risk. PLoS Med 15(6): e1002594.

Author Affiliations:

Pneumonia Program Strategy Team, Bill and Melinda Gates Foundation, Seattle, Washington, United States of America Maternal Neonatal, Child Health Discovery and Tools Program Strategy Team, Bill and Melinda Gates Foundation, Seattle, Washington, United States of America

In your coverage please use this URL to provide access to the freely available paper:


Related Meningitis Articles:

Complications of measles can include hepatitis, appendicitis, and viral meningitis, doctors warn
The complications of measles can be many and varied, and more serious than people might realise, doctors have warned in the journal BMJ Case Reports after treating a series of adults with the infection.
Pneumococcal vaccines are effective -- But new strategies needed to reduce meningitis
Pneumococcal conjugate vaccines (PCVs) have been highly effective in reducing pneumonia and other invasive infections caused by Streptococcus pneumoniae bacteria.
New research uncovers improvements in vaccines against meningitis
New research from experts at the University of Nottingham could lead to an improved vaccine to protect against the bacterium, Neisseria meningitides that causes sepsis and meningitis.
Current treatment for fungal meningitis is fueling drug resistance
A common first-line treatment approach for cryptococcal meningitis in low-income countries is being compromised by the emergence of drug resistance, new University of Liverpool research warns.
An improved vaccine for bacterial meningitis and bloodstream infections
Researchers have now developed a new vaccine, a native outer membrane vesicle (NOMV) vaccine, for meningitis and bloodstream infections caused by 'meningococcal group B' bacteria.
How inhaled fungal spores cause fatal meningitis
Pathogenic fungal spores capitalize on host immune cells to escape the lung and gain access to the brain to cause fatal disease in mice, according to a study published June 27, 2019 in the open-access journal PLOS Pathogens by Christina Hull of the University of Wisconsin-Madison, and colleagues.
New non-antibiotic strategy for the treatment of bacterial meningitis
With the increasing threat of antibiotic resistance, there is a growing need for new treatment strategies against life threatening bacterial infections.
Meningitis changes immune cell makeup in the mouse brain lining
Meningitis, a group of serious diseases which infect the brain's lining, leaves its mark and can affect the body's ability to fight such infections in the future.
Study suggests universal meningitis vaccination is not cost-effective for college students
A computer-generated model developed by Johns Hopkins Medicine researchers adds to evidence that providing universal vaccination against meningitis B infection to students entering college may be too costly to justify the absolute number of cases it would prevent.
Meningitis progress lags substantially behind that of other preventable diseases
The global disease burden of meningitis remains unacceptably high, and progress lags substantially behind that of other vaccine-preventable diseases.
More Meningitis News and Meningitis Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.